News

Agilent Announces Purchase of Boulder Facility

Thursday, July 25, 2019

Agilent Technologies has announced it is purchasing the building in Boulder where they have been manufacturing therapeutic oligonucleotides (“oligos") for over a decade. This $12 million purchase, along with their recent $150 million investment in their second oligo manufacturing site in Frederick, Colorado, more than doubles their capacity to produce oligos and reaffirms Agilent’s confidence in the therapeutic oligo market. Furthermore, it solidifies their commitment to doing business in the state of Colorado and their commitment to be a good corporate citizen in local communities.  

2019 Rocky Mountain Life Science Investor and Partnering Conference Announces Presenting Companies

Wednesday, July 24, 2019

September conference led by Colorado BioScience Association to provide companies from across the region new opportunities for capital access 
Continue Reading

Viewray to Expand to Denver, Adding 274 Jobs

Tuesday, July 16, 2019

Viewray, Inc., an Ohio-based medical technology company that provides high-level MRI-guided radiation technology is expanding its operations in the metro Denver area and will be hiring 274 people over the next eight years.

Read the full story on the Denver Business Journal’s website.

 
Continue Reading

Silvergate Pharmaceuticals Merges With CutisPharma To Serve Patients On Opposite Ends of the Spectrum

Wednesday, July 10, 2019

Silvergate Pharmaceuticals produces pediatric medications, while CutisPharma has served the senior population. They’re bringing their companies together to form Azurity Pharmaceuticals.

While it might initially seem like the two patient groups have little in common, Azurity’s CEO Neal Muni believes joining forces was a very natural move. Both populations often require specialized dosing and may struggle with swallowing pills.

“It made a lot of sense strategically to better serve our patients,” Muni said. “We started talking with Silvergate and their investors quite some time back about the potential opportunity to combine the two companies. With this combination of the two we can reaffirm our commitment to the same patient populations with much larger capability.”

Read the full article on the Denver Business Journal’s website.

 
Continue Reading

Cerapedics Announces Expansion of Colorado Headquarters

Monday, July 08, 2019

WESTMINSTER, Colo., July 8, 2019 /PRNewswire/ -- Cerapedics, a private ortho-biologics company, today announced the expansion of the company's headquarters located in the Denver metropolitan area. Over the past 18 months, Cerapedics has grown from 16 to 44 employees in Colorado and is increasing its facility from 14,000 to 24,000 square feet to accommodate further expansion through the end of 2019. In addition, Cerapedics is expanding its global workforce from 32 to 73 employees worldwide.

"We are excited to grow our Colorado footprint and bring more jobs and career opportunities to the Denver area," said Glen Kashuba, Chief Executive Officer of Cerapedics. "This expansion allows us to further control our value chain by relocating our distribution activities to our corporate headquarters. We now have the potential to double our headcount across key administrative, operational and sales support departments to meet the growing demand for i-FACTOR™ Peptide Enhanced Bone Graft and drive the business for years to come."

Cerapedics commercialized i‑FACTOR beginning in 2016 and has since increased its market space with continued growth of greater than 50% expected in 2019. i-FACTOR is a drug-device combination that accelerates new bone formation in patients with degenerative disc disease. It is in a new category of bone graft technology and is one of only two drug-device combination products approved by the U.S. Food & Drug Administration (FDA).

To further grow its product portfolio and support the company's commitment to enhancing the science of bone repair, Cerapedics is currently enrolling patients in an investigational device exemption (IDE) clinical trial evaluating the safety and efficacy of the next-generation P-15L Peptide Enhanced Bone Graft in transforaminal lumbar interbody fusion (TLIF) surgery.

"We are excited about our future product offering and further advancement of our growing bone graft franchise," said Edward Sawyer, General Manager and Head of Colorado Operations for Cerapedics. "Expanding our facility enables us to double our Colorado staff to best service our customers and our product. We've benefited greatly from our Coloradolocation and are pleased to continue to expand our team of talented professionals. We have found a strong pool of talent upon which to utilize in the Denver Metro Area."

About Cerapedics

Cerapedics is an ortho-biologics company focused on developing and commercializing its proprietary synthetic small peptide (P-15) technology platform. i-FACTOR Peptide Enhanced Bone Graft is the only biologic bone graft in orthopedics that incorporates a small peptide as an attachment factor to stimulate the natural bone healing process. This novel mechanism of action is designed to support safer and more predictable bone formation compared to commercially available bone growth factors. More information can be found at www.cerapedics.com.

CAUTION: P-15L Bone Graft is an Investigational Product limited by Federal (USA) Law to Investigational Use.

Media contact:
Adam Daley
Berry & Company Public Relations
212-253-8881
adaley@berrypr.com

 
Continue Reading

New State-of-the-Art Facility Increases Agilent's Capacity to Produce Nucleic Acid-Based Therapeutics

Tuesday, June 18, 2019

New facility in Frederick, Colorado, to produce high-quality molecules with the potential to treat cancer and other diseases 
Continue Reading

Pfizer to buy Colorado's Array BioPharma in deal worth $11.4 billion

Monday, June 17, 2019

Pharmaceutical giant Pfizer Inc. is delving deeper into cancer research with a roughly $11.4 billion deal for Array BioPharma Inc., a Colorado drug developer that has seen its shares soar since announcing positive clinical trial results earlier this spring.

Pfizer said Monday it will pay $48 per share in cash for Boulder-based Array, whose product portfolio includes a treatment combination used for advanced skin cancer that is being tested in other cancers as well.

Array said last month that its combination of the drugs Braftovi and Mektovi along with another treatment led to a significant improvement in overall survival in late-stage testing for some patients with colorectal cancer.

The company plans to submit results from that study to U.S. regulators for approval later this year.

Array's share price has jumped 41% since late May and more than doubled so far this year. Pfizer's offer of $48 per share represents a premium of 62% to the stock's closing price of $29.59 on Friday.

Shares of Array surged 60% before Monday's opening bell.

New York-based Pfizer, which makes the breast cancer drug Ibrance and the blood thinner Eliquis, said the boards of both companies have approved the deal.

It will finance the deal with debt and cash, and it expects the transaction to add to earnings per share starting in 2022.

Pfizer, the biggest U.S. drugmaker by revenue, has had several drug approvals in the U.S. or elsewhere so far this year. But it also saw a heavily touted pain drug flop in late-stage clinical testing, placing the drug's future in doubt.

Pfizer shares edged down 5 cents to $42.70 in premarket trading.

 
Continue Reading

CutisPharma Announces Acquisition of Silvergate Pharmaceuticals, Name Change to Azurity Pharmaceuticals

Thursday, June 13, 2019

WOBURN, Mass. (Jun. 12, 2019) – CutisPharma, Inc. announced today its acquisition of Silvergate Pharmaceuticals, Inc. and the unveiling of its new corporate brand for the unified company: Azurity Pharmaceuticals.
 

ArcherDX Announces Close of $60M Financing to Advance Companion Diagnostic and Minimal Residual Disease Monitoring Product Portfolio

Wednesday, May 15, 2019

BOULDER, Colo., May, 15, 2019 /PRNEWSWIRE/-- ArcherDX, Inc., a molecular technology company dedicated to developing breakthrough solutions that advance the application of personalized genomic medicine, today announced the closing of an up to $60 million Series B financing round led by Perceptive Advisors. The investor syndicate also includes existing investors PBM Capital, Boulder Ventures, Longwood Fund and Peierls Foundation.  

Prima-Temp Announces New Leadership, Investment, and CE Mark Certification

Wednesday, May 08, 2019

BOULDER, Colo., May 3, 2019 /PRNewswire/ -- Boulder, Colorado based Prima-Temp, Inc. a developer and manufacturer of AI-assisted fertility management products, announced today that in March, it raised $5M in new funding from the Hungarian pharmaceutical company Gedeon Richter, and in April achieved CE mark certification for its Priya Fertility Sensor product.